July 29, 2008 – Hologic said it has made Third Wave Technologies a wholly owned subsidiary of Hologic.
Third Wave develops and markets molecular diagnostic reagents for a wide variety of DNA and RNA analysis applications based on its proprietary Invader Chemistry, said Hologic. Third Wave currently offers clinical diagnostic product for conditions such as cystic fibrosis, hepatitis C, cardiovascular risk and other diseases. Recently Third Wave submitted pre-market approval (PMA) applications for two human papilloma virus, or HPV, tests to the FDA.
For more information: www.hologic.com
March 25, 2026 
